7-(2-hydroxyethyl-amino)-5-methyl-1H-pyrazolo[4,3-b]pyridine | 99930-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 7-(2-hydroxyethyl-amino)-5-methyl-1H-pyrazolo[4,3-b]pyridine
• 英文别名: 7-(2-hydroxyethylamino)-5-methyl-1H-pyrazolo[4,3-b]pyridine；7-[2-hydroxyethylamino]-5-methyl-1H-pyrazolo[4,3-b]pyridine；2-[(5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl)amino]ethanol
• CAS: 99930-16-2
• 化学式: C₉H₁₂N₄O
• 分子量: 192.22
• InChiKey: IBYCUIMFTLVDLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  73.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(2-hydroxyethyl-amino)-5-methyl-1H-pyrazolo[4,3-b]pyridine 在 溴 作用下， 以 甲醇 、 水 为溶剂， 生成 3-Bromo-7-(2-hydroxyethylamino)-5-methyl-1H-pyrazolo-[4,3-b]pyridine
  参考文献：
  名称：

  Pharmaceutically useful pyrazolo[4,3-b]pyridines

  摘要：

  化合物的公式（I）或其盐或溶剂化物：## STR1 ##其中：R.sub.0是氢或C.sub.1-6烷基；或与R.sub.3一起是C.sub.4-6聚亚甲基；R.sub.1和R.sub.2都是氢；或R.sub.1是氢，C.sub.1-6烷基；R.sub.2是CN；CR.sub.5R.sub.6Y，其中R.sub.5和R.sub.6独立选择自氢和C.sub.1-4烷基，Y选择自氢，OR.sub.7或SR.sub.7，其中R.sub.7是氢，C.sub.1-4烷基或C.sub.2-4烷酰基，以及NR.sub.8R.sub.9，其中R.sub.8和R.sub.9独立选择自氢，C.sub.1-4烷基，C.sub.2-4烯基或C.sub.2-4烷酰基，或一起是C.sub.4-6聚亚甲基；或COR.sub.10，其中R.sub.10是OH或C.sub.1-4烷基，或COR.sub.10是药学上可接受的酯或酰胺，或R.sub.2是氢，C.sub.1-6烷基或苯，可选择地被卤素，CF.sub.3，C.sub.1-4烷氧基或C.sub.1-4烷基置换，而R.sub.1是CN，CR.sub.5R.sub.6Y或COR.sub.10，如上所定义的R.sub.2；或R.sub.1和R.sub.2一起形成C.sub.3-C.sub.6聚亚甲基，可选择地被C.sub.1-C.sub.4烷基置换；R.sub.3是氢；或C.sub.1-10烷基或C.sub.3-10环烷基，任选地被羟基，C.sub.1-4烷氧基，硫醇，C.sub.1-4烷基硫醇或NR.sub.11R.sub.12取代，其中R.sub.11和R.sub.12独立选择自氢，C.sub.1-6烷基或C.sub.2-7烷酰基，或一起是C.sub.3-6聚亚甲基；C.sub.2-10烯基；或苯，可选择地被卤素，CF.sub.3，C.sub.1-4烷氧基，C.sub.1-4烷基，羟基，硝基，氰基，C.sub.2-10酰氧基，NR.sub.13R.sub.14，其中R.sub.13和R.sub.14独立选择自氢，C.sub.1-6烷基或C.sub.2-7烷酰基；或COR.sub.15，其中R.sub.15是羟基，C.sub.1-6烷氧基或NR.sub.16R.sub.17，其中R.sub.16和R.sub.17独立选择自氢或C.sub.1-6烷基；或R.sub.3是具有芳香环中最多十个原子的单环或融合双环杂环基团，其中不超过两个选择自氮，氧或硫，除了含有碱性氮的基团，可选择地被一或两个取代基取代，所述取代基选择自卤素，CF.sub.3，C.sub.1-4烷氧基，C.sub.1-4烷基，羟基，硝基，氰基，C.sub.2-10酰氧基，NR.sub.23R.sub.24，其中R.sub.23和R.sub.24独立选择自氢，C.sub.1-6烷基，C.sub.2-7烷酰基或C.sub.1-6烷基磺酰基；或COR.sub.25，其中R.sub.25是羟基，C.sub.1-6烷氧基或NR.sub.26R.sub.27，其中R.sub.26和R.sub.27独立选择自氢或C.sub.1-6烷基；R.sub.4是氢，或C.sub.1-4烷基，苯基或苄基，其中每个在苯环中选择自卤素，CF.sub.3，C.sub.1-4烷氧基或C.sub.1-4烷基并附加在氮原子1或2处；而R.sub.x是C.sub.1-6烷基，卤素，硝基，NR.sub.18R.sub.19，其中R.sub.18和R.sub.19独立选择自氢，C.sub.1-6烷基或C.sub.2-7烷酰基，腈，COOH，CONH.sub.2；苯或苄，可选择地被一或两个卤素，硝基，C.sub.1-6烷氧基，羟基，C.sub.2-7烷酰氧基，NR.sub.18R.sub.19，C.sub.1-6烷基，CF.sub.3，CN取代；噻吩基，呋喃基或吡咯基，可选地N-取代C.sub.1-6烷基，但R.sub.1为氢且R.sub.2和R.sub.x为甲基时，R.sub.0和R.sub.3不能同时为氢，该化合物对于治疗炎症或过敏症状是有用的。

  公开号：

  US04833136A1
• 作为产物：
  描述：

  7-氯-5-甲基-1H-吡唑并[4,3-b]-吡啶 生成 7-(2-hydroxyethyl-amino)-5-methyl-1H-pyrazolo[4,3-b]pyridine
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Certain anti-inflammatory pyrazolo [4,3-b] pyridine 7-amines
  申请人：Beecham Group p.l.c. of Beecham House

  公开号：US04818754A1

  公开（公告）日：1989-04-04

  A compound of the formula (1) or a salt or solvate thereof: ##STR1## in which: R.sub.0 is hydrogen or C.sub.1-6 alkyl; R.sub.1 and R.sub.2 are both hydrogen; or R.sub.1 is hydrogen, C.sub.1-6 alkyl; and R.sub.2 is CN; CR.sub.5 R.sub.6 Y where R.sub.5 and R.sub.6 are independently selected from hydrogen and C.sub.1-4 alkyl and Y is selected from hydrogen, OR.sub.7 or SR.sub.7 where R.sub.7 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, and NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl or together are C.sub.4-6 polymethylene; or COR.sub.10 is OH or C.sub.1-4 alkyl, or COR.sub.10 is a pharmaceutically acceptable ester or amide; or R.sub.2 is hydrogen, C.sub.1-6 alkyl, or phenyl optionally substituted by halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl; and R.sub.1 is CN, CR.sub.5 R.sub.6 Y or COR.sub.10 as defined for R.sub.2 above; or R.sub.1 and R.sub.2 together form C.sub.3 -C.sub.6 polymethylene optionally substituted by C.sub.1 -C.sub.4 alkyl; R.sub.3 is --(CH.sub.2).sub.n CO.sub.2 R.sub.11, --(CH.sub.2).sub.n CONR.sub.12 R.sub.13,--(CH.sub.2).sub.n CN, --(CH.sub.2).sub.m NHCOR.sub.14, ##STR2## where a, b, n, m and p are integers and n is 1 to 10, m is 2 to 10, p is 3 to 5, a is 1 to 3, and b is 1 to 3, and R.sub.11 is hydrogen, C.sub.1-8 alkyl, benzyl or phenyl, R.sub.12 and R.sub.13 are independently hydrogen, C.sub.1-6 alkyl, benzyl or phenyl, or together form C.sub.3-8 alkylene, R.sub.14 is C.sub.1-4 alkyl, benzyl or phenyl and X is oxygen, sulphur, NH or N--C.sub.1-4 alkyl, and R.sub.4 is hydrogen; or C.sub.1-4 alkyl or benzyl optionally substituted in the phenyl ring by one or two of halogen, CF.sub.3, C.sub.1-4 alkoxy or C.sub.1-4 alkyl, and is attached at nitrogen atom 1 or 2, a process for its preparation and its use as a pharmaceutical.

  该化合物的分子式为（1）或其盐或溶剂化合物：##STR1## 其中：R.sub.0为氢或C.sub.1-6烷基；R.sub.1和R.sub.2都是氢；或R.sub.1为氢、C.sub.1-6烷基；而R.sub.2为CN；CR.sub.5 R.sub.6 Y，其中R.sub.5和R.sub.6分别独立选择自氢和C.sub.1-4烷基，Y选择自氢、OR.sub.7或SR.sub.7，其中R.sub.7为氢、C.sub.1-4烷基或C.sub.2-4烷酰基，以及NR.sub.8 R.sub.9，其中R.sub.8和R.sub.9独立地选择自氢、C.sub.1-4烷基、C.sub.2-4烯基或C.sub.2-4烷酰基，或者一起是C.sub.4-6聚亚甲基；或COR.sub.10为OH或C.sub.1-4烷基，或COR.sub.10是药学上可接受的酯或酰胺；或者R.sub.2为氢、C.sub.1-6烷基，或苯基，可选择地被卤素、CF.sub.3、C.sub.1-4烷氧基或C.sub.1-4烷基取代；而R.sub.1为CN、CR.sub.5 R.sub.6 Y或COR.sub.10，如上述R.sub.2的定义；或R.sub.1和R.sub.2一起形成C.sub.3-C.sub.6聚亚甲基，可选择地被C.sub.1-C.sub.4烷基取代；R.sub.3为--(CH.sub.2).sub.n CO.sub.2 R.sub.11，--(CH.sub.2).sub.n CONR.sub.12 R.sub.13，--(CH.sub.2).sub.n CN，--(CH.sub.2).sub.m NHCOR.sub.14，##STR2## 其中a、b、n、m和p为整数，n为1至10，m为2至10，p为3至5，a为1至3，b为1至3，R.sub.11为氢、C.sub.1-8烷基、苄基或苯基，R.sub.12和R.sub.13独立地为氢、C.sub.1-6烷基、苄基或苯基，或一起形成C.sub.3-8烷基，R.sub.14为C.sub.1-4烷基、苄基或苯基，X为氧、硫、NH或N--C.sub.1-4烷基，R.sub.4为氢；或C.sub.1-4烷基或苄基，可选择地在苯环中由卤素、CF.sub.3、C.sub.1-4烷氧基或C.sub.1-4烷基中的一种或两种取代，并连接到氮原子1或2，以及其制备方法和作为药物的用途。
• Pyrazolo[4,3-b]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0239191A2

  公开（公告）日：1987-09-30

  A compound of the formula (I) or a salt or solvate thereof: in which: R₀ is hydrogen or C1-6 alkyl; or together with R₃ is C4-6 polymethylene; R₁ and R₂ are both hydrogen; or R₁ is hydrogen, C1-6 alkyl; and R₂ is CN; CR₅R₆Y where R₅ and R₆ are independently selected from hydrogen and C1-4 alkyl and Y is selected from hydrogen, OR₇ or SR₇ where R₇ is hydrogen, C1-4 alkyl or C2-4 alkanoyl, and NR₈R₉ where R₈ and R₉ are independently hydrogen, C1-4 alkyl, C2-4 alkenyl or C2-4 alkanoyl or together are C4-6 polymethylene; or COR₁₀ where R₁₀ is OH or C1-4 alkyl, or COR₁₀ is a pharmaceutically acceptable ester or amide, or R₂ is hydrogen, C1-6 alkyl, or phenyl optionally substituted by halogen, CF₃, C1-4 alkoxy or C1-4 alkyl, and R₁ is CN, CR₅R₆Y or COR₁₀ as defined for R₂ above; or R₁ and R₂ together form C₃-C₆ polymethylene optionally substituted by C₁-C₄ alkyl; R₃ is hydrogen; or C1-10 alkyl or C3-10 cycloalkyl, either optionally substituted by hydroxy, C1-4 alkoxy, thiol, C1-4 alkylthio or NR₁₁R₁₂ wherein R₁₁ and R₁₂ are independently hydrogen, C1-6 alkyl or C2-7 alkanoyl or together are C3-6 polymethylene; C2-10 alkenyl; or phenyl optionally substituted by one or two of halogen, CF₃, C1-4 alkoxy, C1-4 alkyl, hydroxy, nitro, cyano, C2-10 acyloxy, NR₁₃R₁₄ wherein R₁₃ and R₁₄ are independently selected from hydrogen, C1-6 alkyl, or C2-7 alkanoyl; or COR₁₅ wherein R₁₅ is hydroxy, C1-6 alkoxy or NR₁₆R₁₇ wherein R₁₆ and R₁₇ are independently selected from hydrogen or C1-6 alkyl; or R₃ is a mono- or fused bi-cyclic heteroaryl group having up to ten atoms in the aromatic ring(s), not more than two of which are selected from nitrogen, oxygen or sulphur, other than those containing basic nitrogen, optionally substituted by one or two substituents selected from halogen, CF₃, C1-4 alkoxy, C1-4 alkyl, hydroxy, nitro, cyano, C2-10 acyloxy, NR₂₃R₂₄ wherein R₂₃ and R₂₄ are independently selected from hydrogen, C1-6 alkyl, C2-7 alkanoyl or C1-6 alkylsulphonyl; or COR₂₅ wherein R₂₅ is hydroxy, C1-6 alkoxy or NR₂₆ R₂₇ wherein R₂₆ and R₂₇ are independently selected from hydrogen or C1-6 alkyl; R₄ is hydrogen, or C1-4 alkyl, phenyl or benzyl, each of which is optionally substituted in the phenyl ring by one or two of halogen, CF₃, C1-4 alkoxy or C1-4 alkyl and is attached at nitrogen atom l or 2; and Rx is C1-6 alkyl, halogen, nitro, NR₁₈R₁₉ where R₁₈ and R₁₉ are independently hydrogen, C1-6 alkyl or C2-7 alkanoyl, nitrile, COOH, CONH₂; phenyl or benzyl optionally substituted by one or two of halogen, nitro, C1-6 alkoxy, hydroxy, C2-7 alkanoyloxy, NR₁₈R₁₉, C1-6 alkyl, CF₃, CN; thienyl, furyl or pyrryl optionally N-substituted by C1-6 alkyl, with the proviso that R₀ and R₃ are not both hydrogen when R₁ is hydrogen and R₂ and Rx are methyl, is useful for treating inflammatory or allergic conditions.

  式 (I) 的化合物或其盐或溶液： 其中 R₀ 是氢或 C1-6 烷基；或与 R₃ 一起是 C4-6 聚亚甲基； R₁ 和 R₂ 都是氢； 或 R₁ 是氢、C1-6 烷基；R₂ 是 CN；CR₅R₆Y 其中 R₅ 和 R₆ 独立选自氢和 C1-4 烷基，Y 选自氢、OR₇ 或 SR₇ 其中 R₇ 是氢、C1-4烷基或C2-4烷酰基，以及 NR₈R₉，其中 R₈ 和 R𠢙 独立地为氢、C1-4烷基、C2-4烯基或C2-4烷酰基，或共同为 C4-6 聚亚甲基；或 COR₁₀，其中 R₁₀ 是 OH 或 C1-4 烷基，或 COR₁₀ 是药学上可接受的酯或酰胺、 或 R₂ 是氢、C1-6 烷基或任选被卤素、CF₃、C1-4 烷氧基或 C1-4 烷基取代的苯基，且 R₁ 是 CN、CR₅R₆Y 或 COR₁₀，如上文对 R₂ 所定义； 或 R₁ 和 R₂ 共同形成任选被 C₁-C₄ 烷基取代的 C₃-C₆ 聚亚甲基； R₃是氢；或C1-10烷基或C3-10环烷基，任选被羟基、C1-4烷氧基、硫醇、C1-4烷硫基或NR₁₁R₁₂取代，其中R₁₁和R₁₂独立地是氢、C1-6烷基或C2-7烷酰基，或共同形成C3-6聚亚甲基；C2-10烯基；或任选被卤素、CF₃、C1-4 烷氧基、C1-4 烷基、羟基、硝基、氰基、C2-10 乙酰氧基、NR₁₃R₁₄ 中的一个或两个取代的苯基，其中 R₁₃ 和 R₁₄ 独立选自氢、C1-6 烷基或 C2-7 烷酰基；或 COR₁₅，其中 R₁₅ 是羟基、C1-6 烷氧基或 NR₁₆R₁₇，其中 R₁₆ 和 R₁₇ 独立选自氢或 C1-6 烷基； 或 R₃是单环或融合双环杂芳基，在芳香环中最多有十个原子，其中不超过两个原子选自氮、氧或硫，但含碱基氮的杂芳基除外、可任选被一个或两个取代基取代，这些取代基选自卤素、CF₃、C1-4 烷氧基、C1-4 烷基、羟基、硝基、氰基、C2-10 乙酰氧基、NR₂₃R₂₄，其中 R₂₃ 和 R₂₄ 独立选自氢、C1-6 烷基、C2-7 烷酰基或 C1-6 烷基磺酰基；或 COR₂₅ 其中 R₂₅ 是羟基、C1-6 烷氧基或 NR₂₆ R₂₇ 其中 R₂₆ 和 R₂₇ 独立选自氢或 C1-6 烷基； R₄是氢、或C1-4烷基、苯基或苄基，其中每个苯基环可选择被卤素、CF₃、C1-4烷氧基或C1-4烷基中的一个或两个取代，并连接在氮原子l或2上；和 Rx 是 C1-6 烷基、卤素、硝基、NR₁₈R₁₉，其中 R₁₈ 和 R₁₉ 独立地是氢、C1-6 烷基或 C2-7 烷酰基、腈、COOH、CONH₂；任选被卤素、硝基、C1-6 烷氧基、羟基、C2-7 烷酰氧基、NR₁₈R₁₉、C1-6 烷基、CF₃、CN 中的一个或两个取代的苯基或苄基；任选被 C1-6 烷基 N-取代的噻吩基、呋喃基或吡喃基、 当 R₁ 为氢、R₂ 和 Rx 为甲基时，R₀ 和 R₃ 不能都是氢。
• Pyrazolopyridine derivatives, process for their preparation, and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0243055A2

  公开（公告）日：1987-10-28

  A compound of the formula (1) or a salt or solvate thereof: in which: R₀ is hydrogen or C1-6 alkyl; R₁ and R₂ are both hydrogen; or R₁ is hydrogen, C1-6 alkyl; and R₂ is CN; CR₅R₆Y where R₅ and R₆ are independently selected from hydrogen and C1-4 alkyl and Y is selected from hydrogen, OR₇ or SR₇ where R₇ is hydrogen, C1-4 alkyl or C2-4 alkanoyl, NR₈R₉ where R₈ and R₉ are independently hydrogen, C1-4 alkyl, C2-4 alkenyl or C2-4 alkanoyl or together are C4-6 polymethylene; or COR₁₀ where R₁₀ is OH or C1-4 alkyl, or COR₁₀ is a pharmaceutically acceptable ester or amide; or R₂ is hydrogen, C1-6 alkyl, or phenyl optionally substituted by halogen, CF₃, C1-4 alkoxy or C1-4 alkyl; and R₁ is CN, CR₅R₆Y or COR₁₀ as defined for R₂ above; or R₁ and R₂ together form C3-C6 polymethylene optionally substituted by C1-C4 alkyl; R₃ is -(CH₂)nCO₂R₁₁, -(CH₂)nCONR₁₂R₁₃,-(CH₂)nCN, -(CH₂)mNHCOR₁₄, -(CH₂)m-O--R₁₄ where a, b, n, m and p are integers and n is 1 to 10, m is 2 to 10, p is 3 to 5, a is 1 to 3, and b is 1 to 3, and R₁₁ is hydrogen, C1-8 alkyl, benzyl or phenyl, R₁₂ and R₁₃ are independently hydrogen, C1-6 alkyl, benzyl or phenyl, or together form C3-8 alkylene, R₁₄ is C1-4 alkyl, benzyl or phenyl and X is oxygen, sulphur, NH or N-C1-4 alkyl, and R₄ is hydrogen; or C1-4 alkyl or benzyl optionally substituted in the phenyl ring by one or two of halogen, CF₃, C1-4 alkoxy or C1-4 alkyl, and is attached at nitrogen atom 1 or 2, a process for its preparation and its use as a pharmaceutical.

  式 (1) 的化合物或其盐或溶液： 其中 R₀ 是氢或 C1-6 烷基； R₁ 和 R₂ 都是氢； 或 R₁ 是氢、C1-6 烷基；以及 R₂ 是 CN；CR₅R₆Y 其中 R₅ 和 R₆ 独立选自氢和 C1-4 烷基，Y 选自氢、OR₇ 或 SR₇ 其中 R₇ 是氢、其中 R₈ 和 R𠢙 独立地为氢、C1-4 烷基、C2-4 烯基或 C2-4 烷酰基，或共同为 C4-6 聚亚甲基；或 COR₁₀，其中 R₁₀ 是 OH 或 C1-4 烷基，或 COR₁₀ 是药学上可接受的酯或酰胺； 或 R₂ 是氢、C1-6 烷基或任选被卤素、CF₃、C1-4 烷氧基或 C1-4 烷基取代的苯基；且 R₁ 是 CN、CR₅R₆Y 或 COR₁₀，如上文对 R₂ 所定义； 或 R₁ 和 R₂ 共同形成任选被 C1-C4 烷基取代的 C3-C6 聚亚甲基； R₃ 是 -(CH₂)nCO₂R₁₁, -(CH₂)nCONR₁₂R₁₃, -(CH₂)nCN, -(CH₂)mNHCOR₁₄, -(CH₂)m-O--R₁₄ 其中 a、b、n、m 和 p 为整数，n 为 1 至 10，m 为 2 至 10，p 为 3 至 5，a 为 1 至 3，b 为 1 至 3、 R₁₁ 是氢、C1-8 烷基、苄基或苯基，R₁₂ 和 R₁₃ 独立地是氢、C1-6 烷基、苄基或苯基，或共同形成 C3-8 亚烷基，R₁₄ 是 C1-4 烷基、苄基或苯基，X 是氧、硫、NH 或 N-C1-4 烷基，以及 R₄ 是氢；或在苯基环上被卤素、CF₃、C1-4 烷氧基或 C1-4 烷基中的一个或两个任选取代并连接在氮原子 1 或 2 上的 C1-4 烷基或苄基。
• ——
  作者：

  DOI：——

  日期：——
• pyrazolopyridine derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0152910B1

  公开（公告）日：1989-07-12